Physician profile
John E Vance
NPI 1841301496
$3,669.81
in general payments reported to CMS, 2019-2025
30 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $455 · 2021: $307 · 2022: $432 · 2023: $583 · 2024: $634 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $643.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $517.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $483.13 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $404.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $346.94 | 2022-2025 | |
| Pfizer INC. | $262.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $169.49 | 2019-2024 | Verquvo, Gardasil 9, Belsomra |
| Janssen Pharmaceuticals, INC | $164.46 | 2019-2022 | |
| Sanofi Pasteur INC. | $89.42 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.32 | 2022-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $57.75 | 2019 | |
| Dexcom, INC. | $55.26 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $54.83 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $44.41 | 2024 | Fanapt |
| Abbvie INC. | $35.25 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.72 | 2019-2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $24.92 | 2022-2023 | Quviviq |
| Novavax INC | $23.63 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Averitas Pharma INC. | $19.57 | 2025 | Qutenza |
| Abbott Laboratories | $18.70 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $18.41 | 2025 | Otezla, Repatha |
| Corcept Therapeutics | $17.66 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $17.65 | 2021 | |
| Exact Sciences Corporation | $17.47 | 2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $17.46 | 2021 | |
| Athena Bioscience, LLC | $17.31 | 2024 | Qdolo |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2025 | Trintellix |
| Watermark Medical, INC. | $14.59 | 2024 | |
| Corium, LLC | $10.75 | 2023 | Adlarity |
| Ultragenyx Pharmaceutical INC. | $9.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.